$1.59 Billion is the total value of Sofinnova Investments, Inc.'s 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 65.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZN | Sell | AstraZeneca PLCsponsored adr | $92,291,254 | -24.0% | 1,362,836 | -19.7% | 5.82% | -26.8% |
| ISRG | Sell | Intuitive Surgical Inc | $50,647,134 | -26.4% | 173,277 | -13.9% | 3.20% | -29.1% |
| EXEL | Sell | Exelixis Inc | $18,152,193 | -62.9% | 830,764 | -67.6% | 1.14% | -64.3% |
| SNDX | Sell | Syndax Pharmaceuticals Inc | $13,675,183 | -58.7% | 941,817 | -40.5% | 0.86% | -60.2% |
| INBX | Sell | Inhibrx Inc | $13,639,445 | -47.4% | 743,294 | -25.5% | 0.86% | -49.3% |
| GERN | Sell | Geron Corp | $7,849,398 | -55.0% | 3,702,546 | -31.8% | 0.50% | -56.6% |
| AXSM | Sell | Axsome Therapeutics Inc | $5,616,920 | -56.4% | 80,368 | -55.2% | 0.35% | -58.1% |
| SYBX | Exit | Synlogic Inc | $0 | – | -574,972 | -100.0% | -0.02% | – |
| ALLK | Exit | Allakos Inc | $0 | – | -62,465 | -100.0% | -0.02% | – |
| FGEN | Exit | FibroGen Inccall | $0 | – | -250,000 | -100.0% | -0.04% | – |
| FGEN | Exit | FibroGen Inc | $0 | – | -637,567 | -100.0% | -0.11% | – |
| FGEN | Exit | FibroGen Incput | $0 | – | -650,000 | -100.0% | -0.12% | – |
| VIR | Exit | Vir Biotechnology Incput | $0 | – | -300,000 | -100.0% | -0.48% | – |
| PTCT | Exit | PTC Therapeutics Inc | $0 | – | -260,443 | -100.0% | -0.69% | – |
| VIR | Exit | Vir Biotechnology Inc | $0 | – | -488,117 | -100.0% | -0.78% | – |
| RVMD | Exit | Revolution Medicines Inc | $0 | – | -520,377 | -100.0% | -0.91% | – |
| BAX | Exit | Baxter Intl Inc | $0 | – | -362,200 | -100.0% | -1.08% | – |
| RETA | Exit | Reata Pharmaceuticals Inccl a | $0 | – | -322,471 | -100.0% | -2.15% | – |
| BSX | Exit | Boston Scientific Corp | $0 | – | -608,861 | -100.0% | -2.16% | – |
| VRTX | Exit | Vertex Pharmaceuticals Inc | $0 | – | -145,300 | -100.0% | -3.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.